Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 76 clinical trials
An Open-Label, Multicenter, Phase 1B/2 Study of RP1 in Solid Organ Transplant Recipients With Advanced Cutaneous Malignancies (ARTACUS)

This Phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients. This will include patients with either previous renal, …

squamous cell carcinoma
cytotoxic t-lymphocyte antigen 4
carcinoma
formalin-fixed paraffin-embedded
organ transplantation
  • 22 views
  • 28 Oct, 2022
  • 14 locations
Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers

In this clinical phase I, non-randomized, open-label, uncontrolled, interventional, multi-center trial, 20 adult subjects (≥ 18 years of age) with advanced non-melanoma skin cancers will receive a fixed dose of 0.1 mg of IFx-Hu2.0 intralesionally as monotherapy in up to three lesions at up to three time points. Subjects will …

l-arginine
tumor cells
platelet count
intralesional injection
renal function
  • 2 views
  • 21 Apr, 2022
  • 4 locations
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients With Lymph Node Metastases (ADAM)

This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and have undergone surgery and/or radiation

  • 4 views
  • 16 Oct, 2022
  • 10 locations
Exercise to Boost Response to Checkpoint Blockade Immunotherapy

30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles

ipilimumab
targeted therapy
nivolumab
carcinoma
immunomodulator
  • 0 views
  • 10 Oct, 2022
  • 1 location
Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240

The goal of this study is to execute a small clinical proof of concept trial: To examine the effects of losartan on mucociliary clearance (MCC) in patients not eligible for CFTR rescue therapies

pulse oximetry
fibrosis
oximetry
  • 0 views
  • 22 Mar, 2022
  • 1 location
Shared Decision Making About Medication Use for People With Multiple Health Problems

primary care for patients with mild cognitive impairment or dementia and/or multiple chronic conditions (MCC), the patients' care partners, and clinicians.

Accepts healthy volunteers
dementia
mild cognitive impairment
cognitive impairment
  • 0 views
  • 03 Jun, 2022
  • 1 location
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies (iPREDICT)

response of advanced or metastatic melanoma, Merkel cell carcinoma, renal cell carcinoma, or non-small cell lung cancer tumors to immuno-oncology therapy.

platinum-based chemotherapy
tumor cells
metastatic melanoma
pet scan
atezolizumab
  • 0 views
  • 07 Oct, 2022
  • 7 locations
A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

This is a first-in-human (FIH), Phase 1, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors.

systemic therapy
epidermal growth factor receptor
cytotoxic drug
EGFR
cancer
  • 0 views
  • 23 Oct, 2022
  • 1 location
CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer

CMP-001-009 is a Phase 2 study of intratumoral CMP-001 in combination with an intravenous PD-1-blocking antibody administered to participants with certain types of advanced or metatastic cancer. The primary objective of the study is to determine the Investigator-assessed confirmed objective response with CMP-001 in combination with a programmed cell death …

cancer
  • 0 views
  • 04 Oct, 2022
  • 14 locations
Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma (KAPVEC)

systemic antitumor immunity. In Merkel cell carcinoma (MCC), another virus-induced tumor, treatment with PD-1/PD-L1 axis inhibitors have proven efficacy, thus providing a proof of principle that

cancer chemotherapy
systemic therapy
direct bilirubin
carcinoma
herpes
  • 0 views
  • 30 Jun, 2022
  • 1 location